<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03451032</url>
  </required_header>
  <id_info>
    <org_study_id>RC17_0485</org_study_id>
    <nct_id>NCT03451032</nct_id>
  </id_info>
  <brief_title>Regional Multicenter Study to Evaluate Tolerability and Efficacy of TAF/FTC/RPV Combination (ODEFSEY ®) in Prevention of Sexual or Blood Exposure to HIV</brief_title>
  <acronym>AES ODEFSEY</acronym>
  <official_title>Regional Multicenter Study to Evaluate Tolerability and Efficacy of TAF/FTC/RPV Combination (ODEFSEY ®) in Prevention of Sexual or Blood Exposure to HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multicenter study to evaluate tolerability, adherence and efficacy of a 28-day
      course of TAF/FTC/RPV, an HIV post-exposure prophylaxis after a potential sexual or blood
      exposure to HIV.

      At baseline, participants are prescribed TAF/FTC/RPV and a blood test. At W6, all
      participants are contacted by phone to evaluate completeness and tolerability of the
      TAF/FTC/RPV regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At baseline, participants seek care in one of the centers of &quot; Pays de la Loire &quot; area after
      a potential HIV exposure. They receive TAF/FTC/RPV, one pill taken with food once daily for
      28 days according to national guidelines. They have to start this post-exposure prophylaxis
      within 48 hours after the HIV exposure.

      At inclusion, participants give their written consent to have their data recorded in an
      electronic medical record Nadis® and their oral consent after reading the study information
      letter. A blood test is prescribed to examine biological variables (HIV, HBV, HCV serologies,
      TPHA VDRL, ALT/AST, hemogram and serum creatinine). Characteristics of participants and
      context of the risk are collected in the electronic medical record Nadis®. A blood test is
      prescribed at W2, W6 and W12 to evaluate tolerability and efficacy of the treatment.

      At W6, all participants are contacted by phone call to evaluate completeness and tolerability
      of the TAF/FTC/RPV regimen. They are reminded to have a blood test done at W6 and W12.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants who stopped the 28-day course of TAF/FTC/RPV</measure>
    <time_frame>At 6 weeks</time_frame>
    <description>: Phone call to all participants to check on their adherence and to collect information about possible side effects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who had side effects of the post-exposure prophylaxis with TAF/FTC/RPV</measure>
    <time_frame>At 6 weeks</time_frame>
    <description>Phone call to all participants to collect information about possible side effects.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hiv</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non Interventional Study</intervention_name>
    <description>Non Interventional Study</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Persons included in the study are adults who seek care in one of the French CEGIDD or in
        one of the French centers of &quot; Pays de la Loire &quot; area after a potential sexual or blood
        HIV exposure with an indication of HIV post-exposure prophylaxis according to the French
        guidelines.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject seeking care in one of the French CEGIDD or in one of the French centers of &quot;
             Pays de la Loire &quot; area (CHU Nantes, CHU Angers, CHD La Roche sur Yon, CH Le Mans, CH
             Saint Nazaire, CH Laval) after a potential sexual or non-sexual HIV exposure

          -  Adult ≥18 years old

          -  Oral informed consent

          -  Written informed consent to have their data recorded in an electronic medical record
             (&quot;Nadis&quot; software).

          -  Indication of HIV post-exposure prophylaxis according to the French guidelines

        Exclusion Criteria:

          -  Subject not willing or refusing to participate

          -  Subject on legal protection

          -  HIV positive status

          -  Pregnancy or breastfeeding

          -  Already treated by pre exposure prophylaxis

          -  Already included in the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bénédicte BONNET, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bénédicte BONNET, Dr</last_name>
    <phone>02 40 08 31 12</phone>
    <phone_ext>+033</phone_ext>
    <email>benedicte.bonnet@chu-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Solène SECHER</last_name>
    <phone>02.40.08.31.04</phone>
    <email>solene.secher@chu-nantes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Angers University Hospital</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascale FIALAIRE, Dr</last_name>
      <phone>02 41 35 78 46</phone>
      <email>pafialaire@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Pascale FIALAIRE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>La Roche sur Yon Hospital</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique MERRIEN, Dr</last_name>
      <phone>02 51 44 64 95</phone>
      <email>dominique.merrien@chd-vendee.fr</email>
    </contact>
    <investigator>
      <last_name>Dominique MERRIEN, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Laval Hospital</name>
      <address>
        <city>Laval</city>
        <zip>53000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rémi VATAN, Dr</last_name>
      <phone>02 43 66 50 80</phone>
      <email>remi.vatan@chlaval.fr</email>
    </contact>
    <investigator>
      <last_name>Rémi VATAN, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Le Mans Hospital</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hikombo HITOTO, Dr</last_name>
      <phone>02 43 43 25 14</phone>
      <email>hhitoto@ch-lemans.fr</email>
    </contact>
    <investigator>
      <last_name>Hikombo HITOTO, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bénédicte Bonnet, Dr</last_name>
      <phone>02 40 08 31 12</phone>
      <email>benedicte.bonnet@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Bénédicte Bonnet, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint-Nazaire Hospital</name>
      <address>
        <city>Saint-Nazaire</city>
        <zip>44600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe MICHAUD, Dr</last_name>
      <phone>02 72 27 83 94</phone>
      <email>c.michau@ch-saintnazaire.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe MICHAUD, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2018</study_first_submitted>
  <study_first_submitted_qc>February 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2018</study_first_posted>
  <last_update_submitted>February 23, 2018</last_update_submitted>
  <last_update_submitted_qc>February 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV exposition treatment</keyword>
  <keyword>sexual risk</keyword>
  <keyword>blood risk</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

